Boldebolin is an anabolic steroid indicated for the treatment of muscle atrophy in cancer patients and HIV/AIDS patients.
Like other AAS, boldenone is an agonist of the androgen receptor (AR). The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable methandienone, for androgen deficiency disorders. Boldenone acts similar to methandienone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and associated progestogenic side effects.